Question 1

What is IGF-1 LR3?

Accepted Answer

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with an extended half-life of approximately 20-30 hours compared to minutes for native IGF-1. The modifications include an arginine substitution at position 3 and a 13-amino acid extension at the N-terminus, which reduce binding to IGF binding proteins (IGFBPs).

Question 2

What are the research benefits of IGF-1 LR3?

Accepted Answer

Research on IGF-1 LR3 has investigated its potential effects in several areas, including: Extended half-life (20-30 hours vs minutes for native IGF-1); Potent stimulator of muscle protein synthesis; Studied for muscle growth and recovery; Activates satellite cells for muscle repair. These findings are primarily from preclinical and animal studies unless otherwise noted. Results may not translate directly to humans.

Question 3

How does IGF-1 LR3 work?

Accepted Answer

IGF-1 LR3 binds to IGF-1 receptors throughout the body, activating the PI3K/Akt signaling pathway which promotes protein synthesis, cell proliferation, and anti-apoptotic signaling. Its reduced affinity for IGFBPs means more free IGF-1 LR3 is available to activate receptors compared to native IGF-1. This results in enhanced muscle protein synthesis, satellite cell activation, and nutrient partitioning.

Question 4

What is the FDA/legal status of IGF-1 LR3?

Accepted Answer

IGF-1 LR3 is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is available for research use only. It has not been evaluated for safety or efficacy in humans by regulatory agencies. Always consult applicable laws in your jurisdiction before purchase or use.

Question 5

What are the known risks or side effects of IGF-1 LR3?

Accepted Answer

Based on available research, IGF-1 LR3 has been associated with the following in study settings: Hypoglycemia (IGF-1 has insulin-like effects); Joint pain and swelling; Potential organ growth with prolonged use; Theoretical cancer concerns (promotes cell proliferation). Long-term safety data in humans is limited or absent for most research peptides. This should not be taken as a complete safety profile.

Question 6

Where can I find published research on IGF-1 LR3?

Accepted Answer

Published research on IGF-1 LR3 can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for "IGF-1 LR3" or its aliases (Long R3 IGF-1, LR3-IGF-1) to find peer-reviewed studies. PEP.WIKI aggregates key studies with abstracts and study type classifications on each compound's research page.

IGF-1 LR3

Overview

Mechanism of Action

Key Research Benefits

Clinical Evidence Summary

Key Studies / PubMed References

IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.

Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration.

Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.

Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets.

Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris.

Side Effects & Safety

Known Interactions

Frequently Asked Questions

Research Disclaimer